Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Using the ATM or

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Nov 14, 2022 6:57pm

219 Views

Post# 35098279

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Using the ATM or

Oh, ONC has stated AWARE-1 final data wil be released Q4 2022, so that is due within the next 6 weeks.

I thought that was coming with this last presentation, but... soon.

And we should know the bio-marker data at that time.

IMHO the science is there. Go read all the last NRs.

I am not making this up.

Good luck!

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter